Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. It develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. Show more
Location: 645 Summer Street, Boston, MA, 02210, United States | Website: https://ikenaoncology.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
66.6M
52 Wk Range
$0.97 - $1.94
Previous Close
$1.38
Open
$1.41
Volume
173,778
Day Range
$1.33 - $1.43
Enterprise Value
-42.78M
Cash
114.1M
Avg Qtr Burn
-9.566M
Insider Ownership
8.00%
Institutional Own.
76.25%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
IK-175 (AHR Inhibitor) Details Bladder cancer, Solid tumor/s, Cancer, Urothelial carcinoma | Phase 1b Update | |
IK-595 (MEK-RAF Molecular Glue) Details Cancer, Solid tumor/s | Phase 1 Data readout | |
IK-930 (TEAD1) Details Cancer, Solid tumor/s, Non-small cell lung carcinoma | Failed Discontinued | |
IK-007 Details Solid tumor/s, Colorectal cancer , Cancer | Failed Discontinued |